Latest News

In his present role as vice-president of corporate business development at Eli Lilly, he oversees acquisitions, private equity deals, partnering and corporate venturing.

How to structure a corporate venturing group to meet the different requirements for investing over 30 to 50 years as well as three to 10 years.

Carlsen is on the board of PTC Therapeutics and Santaris Pharma, and was previously a board member of 7TM Pharma and Arpida.

Blausteinwas director of the University Intellectual Property Programme at DuPont from 2004 to 2008. He previously worked at DuPont in research and development portfolio management from 2000 to 2004 and as a business director for non-wovens in Europe from 1997 to 1999.

Asanuma was previously a director at Yasuda Enterprise Development America, a venture firm backed by Japan-based insurers Sompo Japan Insurance and Meiji Yasuda Life Insurance.

With such sizeable funding in place, if Intarcia can carry out a successful trial it would be in a stronger position to reap the returns of what could be a blockbuster treatment worth billions of dollars per year as well as a technology potentially applicable in other areas.